苏帕
尿激酶受体
局灶节段性肾小球硬化
足细胞
医学
肾移植
移植
免疫学
尿激酶
肾
内科学
病理
蛋白尿
作者
Changli Wei,Shafic El Hindi,Jing Li,Alessia Fornoni,Nelson Goes,Junichiro Sageshima,Dony Maiguel,S. Ananth Karumanchi,Hui‐Kim Yap,Moin A. Saleem,Qingyin Zhang,Boris Nikolic,Abanti Chaudhuri,Pirouz Daftarian,Eduardo Salido,Armando Torres,Moro Salifu,Minnie Sarwal,Franz Schaefer,Christian Morath
出处
期刊:Nature Medicine
[Springer Nature]
日期:2011-07-31
卷期号:17 (8): 952-960
被引量:818
摘要
Focal segmental glomerulosclerosis (FSGS) is a cause of proteinuric kidney disease, compromising both native and transplanted kidneys. Treatment is limited because of a complex pathogenesis, including unknown serum factors. Here we report that serum soluble urokinase receptor (suPAR) is elevated in two-thirds of subjects with primary FSGS, but not in people with other glomerular diseases. We further find that a higher concentration of suPAR before transplantation underlies an increased risk for recurrence of FSGS after transplantation. Using three mouse models, we explore the effects of suPAR on kidney function and morphology. We show that circulating suPAR activates podocyte β(3) integrin in both native and grafted kidneys, causing foot process effacement, proteinuria and FSGS-like glomerulopathy. Our findings suggest that the renal disease only develops when suPAR sufficiently activates podocyte β(3) integrin. Thus, the disease can be abrogated by lowering serum suPAR concentrations through plasmapheresis, or by interfering with the suPAR-β(3) integrin interaction through antibodies and small molecules targeting either uPAR or β(3) integrin. Our study identifies serum suPAR as a circulating factor that may cause FSGS.
科研通智能强力驱动
Strongly Powered by AbleSci AI